Zealand Pharma

	11/11 10:05 af Svingtraderen	samme spørgsmål
	11/11 10:05 af Munchi	hvad sker der her til morgen ? 179
	11/11 09:37 af Helge Larsen/PI-redaktør	Spørgsmål til Q&A er meget velkommen. Jo før jo bedre. :-)
	11/11 09:31 af exitnu	ILM :-)
	11/11 09:30 af Svingtraderen	og tak @exitnu
	11/11 09:29 af Svingtraderen	22:21 synes det er væltet ind med nyheder i min Q3 - aktien er steget fra 75 til 190. Er op ca 30% i år mens markedet er ned 20%. Kan ikke liiige se hvad der mangler:)
	11/11 09:27 af Svingtraderen	morning i klubben:)
	11/11 09:18 af ProInvestorNEWS	(link)
	11/11 09:12 af exitnu	Plus disse fire begivenheder: Presented preclinical data at the Annual Meeting of the Obesity Society (Obesity Week). Reported results from the Boehringer Ingelheim-sponsored Phase 2 clinical trial of BI 456906 (GCGR/GLP-1R) in patients with T2D at Obesity Week. Phase 2 trial of BI 456906 in patients with non-alcoholic steatohepatitis (NASH). Received gross proceeds of DKK 786 million from a directed issue and private placement.
	11/11 09:08 af exitnu	@Pensionisten - gider du venligst uddybe - tak!
	11/11 09:07 af exitnu	Personligt synes jeg at Zealand Pharma har overpræsteret. Alt går deres/vores vej ...
	11/11 09:05 af exitnu	Announced a global license and development agreement with Novo Nordisk to commercialize ZEGALOGUE® (dasiglucagon) for injection.
	11/11 09:05 af exitnu	Completed dose escalation in the ongoing Phase 1a single ascending dose (SAD) trial of ZP8396, a long-acting amylin analogue.
	11/11 09:04 af exitnu	Presented results from the Phase 3 clinical trial of dasiglucagon in congenital hyperinsulinism (CHI) at the 60th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE).
	11/11 09:04 af exitnu	Reported results from the Boehringer Ingelheim-sponsored Phase 2 clinical trial of BI 456906, a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, in patients with type 2 diabetes (T2D) at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD).
	11/11 09:04 af exitnu	Announced positive topline results from the pivotal Phase 3 EASE-1 trial of glepaglutide, a long-acting GLP-2 analogue designed for subcutaneous delivery via auto-injector, in patients with short bowel syndrome (SBS).
	11/11 09:04 af exitnu	"Jeg kan, på ingen måde, se at selskabet skulle være en investering værd" JA der er fx sket alt for lidt i Q3:
	11/11 08:45 af ungeee	22.21 - ikke for at lave ballade, men hvilken planet er du på? Eller er du ude på sjov :-)
	11/11 08:32 af exitnu	God morgen :-)
	11/11 07:29 af Stroka	God morgen :-)
	11/11 07:21 af Helge Larsen/PI-redaktør	Godmorgen :-)
	10/11 19:13 af ProInvestorNEWS	Zealand Pharma Q3: Omsætning dykker og underskud vokser (link)
	10/11 18:00 af exitnu	Luk i 189,50 & -1,66%. God aften :-)
	10/11 17:32 af exitnu	Tydeligvis en glitch - desværre.

	10/11 17:31 af EliotSpitzer	Det var en fin lille gennemgang af situationen. Finacial targets bliver fastholdt og ingen overraskelser. Jeg troet at BI var lidt længere fremme end det som blev fremlagt. Men det er min fejl at jeg ikke havde styr på dette.
	10/11 17:30 af exitnu	Operator virkede da også uøvet
	10/11 17:30 af Svingtraderen	tak
	10/11 17:29 af EliotSpitzer	Ingen overraskelser i det C onference call
	10/11 17:29 af exitnu	Teknisk fejl - øv!
	10/11 17:28 af EliotSpitzer	Der var ikke mange spørgsmål "fra salen" men det kan skyldes at operator havde problmer med forbindelsen.
	10/11 17:01 af EliotSpitzer	Jeg er klar
	10/11 16:59 af exitnu	CC nu!
	10/11 16:20 af exitnu	"hosted" skal vel være "to host" :)
	10/11 16:19 af exitnu	Zealand Pharma hosted a conference call on November 10 at 4pm CET (10am ET) to present third quarter results for 2022. (link)
	10/11 16:17 af exitnu	Alt kurspåvirkende skal jo også meldes ud til markedet på forhånd ;)
	10/11 16:16 af Helge Larsen/PI-redaktør	Non event.
	10/11 16:15 af Svingtraderen	tak
	10/11 16:14 af exitnu	Nej intet "breaking".
	10/11 16:14 af Helge Larsen/PI-redaktør	ZEAL - Financial Results for the First Nine Months 2022 (link)
	10/11 16:12 af Svingtraderen	ser i noget "breaking"?
	10/11 16:09 af exitnu	.... • Potential submission of new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for dasiglucagon treatment in the management of CHI in the first half of 2023, based on data from the full Phase 3 program.
	10/11 16:08 af exitnu	Upcoming events • Initiate Phase 1b MAD trial of ZP8396, a long-acting amylin analogue in development for obesity by the end of the fourth quarter 2022. • Interim Phase 3 data from EASE-SBS 2 and 3 long term extension trials of glepaglutide expected by the end of the fourth quarter 2022, and first quarter of 2023, respectively.
	10/11 16:06 af exitnu	Zealand Pharma fastholder forventningerne til regnskabsåret 2022 om nettodriftsomkostninger omkring 1000 mio. kr., mens selskabet har suspenderet forventningerne til produktsalget. Det fremgår af biotekselskabets regnskab for tredje kvartal af 2022. .\\˙ MarketWire
	10/11 16:06 af exitnu	Zealand Pharma Q3: Fastholder forventninger til driftsomkostninger
	10/11 16:04 af exitnu	9M 2022 Interim report (link)
	10/11 16:03 af exitnu	.... In 2022, Zealand expects revenue from existing license agreements. However, since such revenue is uncertain in terms of size and timing, Zealand does not intend to provide guidance on such revenue. Net operating expenses in 2022 are expected to be DKK 1,000 million +/-10%*. This is unchanged from our updated guidance issued on March 30, 2022.
	10/11 16:03 af exitnu	Financial guidance for 2022 The company will no longer provide guidance on net product revenue, reflecting the completion of the asset purchase agreement for V-Go® with MannKind Corporation and the completion of the global license and development agreement for Zegalogue® with Novo Nordisk.
	10/11 16:02 af exitnu	(link)
	10/11 16:01 af exitnu	Zealand Pharma Announces Financial Results for the First Nine Months of 2022 Financial results for the first nine months of 2022 • Revenue: DKK 80.1 million (DKK 95.1 million in the first nine months of 2021). • Net operating expenses: DKK -675.7 million (DKK -652.8 million in the first nine months of 2021). • Net operating result: DKK -596.2 million (DKK -568.7 million in the first nine months of 2021). • Net financial items: DKK -53.4 million (DKK 21.5 million in the first nine months of 202
	10/11 16:00 af Svingtraderen	kom så ZP